3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
CNS
1
Conditions
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Recurrence
1
Neuroblastoma
1
Neoplasms
1
Melanoma
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Glioma
1
Ependymoma
1
Interventions
trametinib
3
dabrafenib
3
Paclitaxel
2
Nivolumab
2
ulixertinib
1
trastuzumab biosimilar HLX02
1
sargramostim
1
sapanisertib
1
romidepsin
1
ripretinib
1
relatlimab
1
pertuzumab
1
palbociclib
1
osimertinib
1
omipalisib
1
olutasidenib
1
liposomal doxorubicin
1
larotrectinib
1
ipatasertib
1
erdafitinib
1
entrectinib
1
entinostat
1
defactinib
1
copanlisib
1
cobimetinib
1
carboxyamido-triazole
1
capmatinib
1
capivasertib
1
binimetinib
1
bempegaldesleukin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioma
×
bempegaldesleukin
×
Other hematologic neoplasm
×
Clear all
NCT04730349
2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2
Terminated
15 enrolled
14 charts